Résumé
Background@#The present study was designed to investigate the antigiardial efficacy of low metronidazole dose loaded-D.L-lactide-co-glycolide (LMD-PLGA) nanoparticles (NPs) and to compare it with the standard high dose of metronidazole either free (HMD) or loaded on PLGA (HMD-PLGA). @*Materials and Methods@#PLGA NPs were prepared by single emulsification method, metronidazole (MTZ) was loaded in low and high doses. The nanoparticles were evaluated in vivo for mice model. The Giardia intestinalis infected mice were treated by LMD and HMD either free or PLGA NPs loaded, the parasitic load and ployclonal antigiardial serum antibodies (IgG and IgA) were recorded. Histopathological studies on intestinal and liver sections were applied. @*Results@#MTZ-PLGA NPs was successfully prepared with 81.68% encapsulation efficiency and with an average particle size of approximately 228.00 ± 43.19 nm and -32.28 ± 0.07 mV Zeta potential. Experimentally, it was observed that Giardia intestinalis infected animals administered with LMD-PLGA had completely eliminated cyst shedding and trophozoite count compared with Giardia-infected mice. Further, it was found that animals belonging to LMD-PLGA group had significantly reduced levels of antigiardial IgA (0.99 ± 0.05) antibodies in serum compared with Giardia-infected. Histopathologyically, also animals belonging to LMD-PLGA treated group had intact mucosal epithelium lining, and normal villi with no detection of G. intestinalis trophozoites. In addition to the less toxic effect on the liver tissue compared to free HMD, HMD-PLGA and infected-untreated groups using Ishak grading system. @*Conclusion@#Our study showed that PLGA nanoparticles could be atrial delivery systems for antigiardial drugs to improve their therapeutic efficacy and minimize their side effects that results from frequent dosing.
Résumé
Background@#The present study was designed to investigate the antigiardial efficacy of low metronidazole dose loaded-D.L-lactide-co-glycolide (LMD-PLGA) nanoparticles (NPs) and to compare it with the standard high dose of metronidazole either free (HMD) or loaded on PLGA (HMD-PLGA). @*Materials and Methods@#PLGA NPs were prepared by single emulsification method, metronidazole (MTZ) was loaded in low and high doses. The nanoparticles were evaluated in vivo for mice model. The Giardia intestinalis infected mice were treated by LMD and HMD either free or PLGA NPs loaded, the parasitic load and ployclonal antigiardial serum antibodies (IgG and IgA) were recorded. Histopathological studies on intestinal and liver sections were applied. @*Results@#MTZ-PLGA NPs was successfully prepared with 81.68% encapsulation efficiency and with an average particle size of approximately 228.00 ± 43.19 nm and -32.28 ± 0.07 mV Zeta potential. Experimentally, it was observed that Giardia intestinalis infected animals administered with LMD-PLGA had completely eliminated cyst shedding and trophozoite count compared with Giardia-infected mice. Further, it was found that animals belonging to LMD-PLGA group had significantly reduced levels of antigiardial IgA (0.99 ± 0.05) antibodies in serum compared with Giardia-infected. Histopathologyically, also animals belonging to LMD-PLGA treated group had intact mucosal epithelium lining, and normal villi with no detection of G. intestinalis trophozoites. In addition to the less toxic effect on the liver tissue compared to free HMD, HMD-PLGA and infected-untreated groups using Ishak grading system. @*Conclusion@#Our study showed that PLGA nanoparticles could be atrial delivery systems for antigiardial drugs to improve their therapeutic efficacy and minimize their side effects that results from frequent dosing.
Résumé
The study demonstrated the immunodiagnostic potential of differrent Egyptian human Schistosoma haematobium antigens. ELISA was used to measure the levels of total immunoglobulin G [IgG] and IgG4 antibodies [Abs] against S. haematobium adult worm antigens [Ags] [SAWA], excretory/ secretory Ags [E/S] and cysteine proteinase Ag [27-29 kDa] for diagnosis of schistosomiasis. SDS-PAGE profiles of S. haematobium Ags showed several bands for SAWA, E/S and 27-29 kDa Ags which are characteristic of infections with Schistosoma spp. Purified protein fraction showed a single homogenous band of 27-29 kDa. For summarizing the potency of S. haematobium Ags, sensitivety rate, negative predictive value and diagnostic efficacy were calculated between data of 40 human patients in ELISA. SAWA Ag recorded 85.0%, 77%, 90.0% with total IgG and 90.0%, 83% and 93.3% with IgG4 isotype, respectively. While, E/S recorded 87.5%, 80%, 92.0% with total IgG and 92.5%, 87%, 95.0% with IgG4 isotype, respectively. Purified 27-29 kDa Ag presents the higher significant [P<0.01] results recording 90.0%, 83%, 93.3% with total IgG and 97.5%, 95%, 98.3% with IgG4 isotype, respectively. The results proved that combining the detection of IgG4 isotype using the 27-29 kDa Ag in sera of schistosomiasis haematobium patients in ELISA test could represent an effective immunodiagnostic tool for detecting infection in low worm burden population. This test could be useful in sero-epidemiolocal studies in low endemic areas and in diagnosis of infection in travelers to schistosomiasis endemic areas